Assessing the Safety and Effectiveness of Devices after FDA Approval

Pew research on U.S. Food and Drug Administration postmarket surveillance studies appeared in the October issue of The Journal of the American Medical Association Internal Medicine. Postmarket surveillance—monitoring the safety and effectiveness of products once they are on the market—allows FDA to more quickly identify problems and accurately measure device performance and clinical outcomes. 

The research found that study protocols frequently were not finalized at the time of approval, which contributes to delays in initiating and completing these studies. Additionally, small sample sizes and lack of availability of findings   limit the clinical usefulness of the studies.

One way to address some of the limitations identified by the authors—including Rita Redberg, a cardiologist at the University of California, San Francisco—is through the wider use of medical device registries, which can quickly and efficiently collect data on large numbers of patients.

Read the full article (subscription required).

Authors: Ian Reynolds, MPH; Josh Rising, MD, MPH; Allan Coukell, BScPharm; Kirsten Paulson, MS; Rita F. Redberg, MD, MSc

National Homeownership Month

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.